What Question Were You Investigating? Ovarian cancer is the fourth leading cause of cancer mortality amongst women and is characterized by late detection, extensive metastasis and poor prognosis. One the reasons that treating this disease has been so challenging is that tumors often become resistant to chemotherapies, and generally respond poorly to immunotherapies. While much […]
Category Archives: Cancer and neoplasms
“Don’t eat me!” That’s how one might translate the signal that the cancer cells in a glioblastoma send to the macrophages (white blood cells specialized in removing dead and dying cellular matter) in the brain. Immunotherapy attempts to enable these cells to eradicate the abnormal cells, but so far, it has met with little success […]
19
Jul
Jul
Lenvatinib (Lenvima) with pembrolizumab (Keytruda) elicited higher, more durable responses and improved survival outcomes compared with sunitinib (Sutent) in the treatment of patients with advanced renal cell carcinoma (RCC), according to findings from the phase 3 CLEAR study (NCT02811861). In data presented at the 2023 Kidney Cancer Research Summit, the objective response rate (ORR) was […]
HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments include promising results from combining immunotherapy […]
19
Jul
Jul
Ahmad Ozair, MBBS Surgically targeted radiation therapy (STaRT) in patients with recurrent glioblastoma (GBM) demonstrated feasibility and safety, according to early data from a prospective multi-institutional observational study (NCT04427384).1 Findings from the trial were presented at the 2023 ASCO Annual Meeting and showed that at a median follow-up of 5.2 months (range, 0.6-23.2), there were […]
19
Jul
Jul
Fam-trastuzumab deruxtecan-nxki (Enhertu) elicited clinically meaningful response in patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer, according to findings from the phase 2 DESTINY-Gastric02 trial (NCT04014075).1 Results from the primary and updated analysis of the study published concurrently in Lancet Oncology. Among patients who had disaese progression after treatment with trastuzumab (Herceptin), patients treated […]
– Data Provide Further Support for Company’s Ongoing Phase 3 Study Evaluating Selinexor as Maintenance Therapy Following Systemic Therapy in Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer – NEWTON, Mass. , July 19, 2023 /PRNewswire/ — Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that an updated […]